Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.

Summary

In a phase 3, double-blind RCT of 610 adults with overweight/obesity, once‑weekly mazdutide 4 or 6 mg produced −11.0% to −14.0% mean weight loss at 48 weeks, with 35.7–49.5% achieving ≥15% weight reduction. Cardiometabolic measures improved broadly, and gastrointestinal adverse events were mostly mild-to-moderate with low discontinuation rates.

Key Findings

• At 48 weeks, mean weight change was −11.00% (4 mg) and −14.01% (6 mg) vs 0.30% with placebo.
• At week 32, ≥5% weight loss occurred in 73.9% (4 mg) and 82.0% (6 mg) vs 10.5% with placebo; ≥15% at week 48 in 35.7% and 49.5% vs 2.0%.
• Cardiometabolic measures improved across all prespecified endpoints; GI adverse events predominated and were mostly mild-to-moderate with low discontinuation.

Clinical Implications

Mazdutide could expand pharmacologic options for obesity in cardiometabolic care, potentially enabling greater weight loss than traditional monotherapies and improving BP, lipids, and glycemia; long-term CV outcome data will be essential for guideline integration.

Limitations

• Single-country (China) population may limit global generalizability
• 48-week duration without adjudicated cardiovascular outcomes limits inference on hard endpoints

Future Directions

Conduct multi-ethnic, longer-term outcome trials to evaluate cardiovascular and renal endpoints, durability of weight loss, and comparative effectiveness vs other incretin-based agents.